Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.59 |
| ▸ | PDE4A | P27815 | 15/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558312 | 0.93 | MEN1 (0.61) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL2827366 | 0.93 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL558606 | 0.92 | MEN1 (0.60) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL23325964 | 0.89 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL7381516 | 0.88 | PDE4B (0.75) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL20212220 | 0.86 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL30036887 | 0.86 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL26463843 | 0.86 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL6360155 | 0.86 | PDE4A (0.53) | PDE4BPDE4APDE4CPDE4DKMT2A | |
| SCHEMBL6354799 | 0.86 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132108-A1 | PREPARATION OF MESEMBRINE | KANNA HEALTH LTD (GB) | 2026-05-14 | — | — | US | claimed |
| EP-4598904-A1 | PREPARATION OF MESEMBRINE | Kanna Health Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| WO-2024074831-A1 | PREPARATION OF MESEMBRINE | Kanna Health Limited (GB) | 2024-04-11 | — | — | WO | claimed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | claimed |
| US-20260132108-A1 | PREPARATION OF MESEMBRINE | KANNA HEALTH LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260049055-A1 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | SENSORIUM THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4637923-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | Sensorium Therapeutics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4598904-A1 | PREPARATION OF MESEMBRINE | Kanna Health Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025122822-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025111234-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025101939-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1713780-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20050239841-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | disclosed |
| US-20050192339-A1 | Compounds | BIOVITRUM AB (SE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051380-A1 | SUBSTITUTED UREA-OCTAHYDROINDOLS AS ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, QPCT, GLS2 | PDE4B 81/4885PDE4A 62/4885PDE4C 56/4885 |
| US-20260132108-A1 | PREPARATION OF MESEMBRINE | BHMT, TMSB10, MSMO1 | PDE4B 2228/4885PDE4A 2194/4885PDE4C 2330/4885 |
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | ADRA1B, HTR1B, ADRB1 | PDE4B 1360/4885PDE4A 1948/4885PDE4C 2729/4885 |
| US-20050192339-A1 | Compounds | MCHR1, HCRTR1, NPY1R | PDE4B 1057/4885PDE4A 1081/4885PDE4C 1334/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | PDE4B 793/4885PDE4A 574/4885PDE4C 687/4885 |
| US-20260049055-A1 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | SLC6A2, SLC6A4, HTR2A | PDE4B 2788/4885PDE4A 3108/4885PDE4C 3155/4885 |
| US-20050239841-A1 | New compounds | MCHR1, NPY1R, HCRTR1 | PDE4B 815/4885PDE4A 897/4885PDE4C 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.